SMTI - Sanara MedTech Inc. Stock Price, Fair Value and News

32.89USD-1.17 (-3.44%)Delayed as of 16 May 2024, 10:17 am ET

Market Summary

USD32.89-1.17

Delayedas of 16 May 2024, 10:17 am

-3.44%

SMTI Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

SMTI Stock Price

View Fullscreen

SMTI RSI Chart

SMTI Valuation

Market Cap

293.8M

Price/Earnings (Trailing)

-60.08

Price/Sales (Trailing)

4.32

EV/EBITDA

-113.43

Price/Free Cashflow

-86.35

SMTI Price/Sales (Trailing)

SMTI Profitability

Operating Margin

88.80%

EBT Margin

-10.86%

Return on Equity

-11.37%

Return on Assets

-6.9%

Free Cashflow Yield

-1.16%

SMTI Fundamentals

SMTI Revenue

Revenue (TTM)

68.0M

Rev. Growth (Yr)

19.42%

Rev. Growth (Qtr)

4.79%

SMTI Earnings

Earnings (TTM)

-4.9M

Earnings Growth (Yr)

-45.04%

Earnings Growth (Qtr)

-787.61%

Breaking Down SMTI Revenue

52 Week Range

30.0346.40

(Low)(High)

Last 7 days

3.5%

Last 30 days

5.4%

Last 90 days

-15.0%

Trailing 12 Months

-12.8%

How does SMTI drawdown profile look like?

SMTI Financial Health

Current Ratio

1.35

Debt/Equity

0.2

Debt/Cashflow

-0.35

SMTI Investor Care

Shares Dilution (1Y)

2.89%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	68.0M	0	0	0
2023	53.6M	59.6M	62.6M	65.0M
2022	26.9M	30.3M	37.6M	45.8M
2021	15.6M	18.9M	20.4M	24.1M
2020	15.8M	15.7M	17.1M	17.1M
2019	6.4M	7.1M	8.5M	11.8M
2018	6.7M	7.5M	7.5M	5.8M
2017	6.0M	6.2M	6.4M	6.3M
2016	3.5M	4.0M	4.5M	5.5M
2015	3.0M	3.2M	3.4M	3.4M
2014	2.0M	2.2M	2.4M	2.6M
2013	1.4M	1.6M	1.7M	1.7M
2012	1.4M	1.4M	1.6M	1.2M
2011	1.2M	1.6M	1.9M	2.2M
2010	0	0	0	910.4K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sanara MedTech Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	waldrop jacob a.	acquired	-	-	3,101	chief operating officer
Mar 07, 2024	mcneil michael d.	acquired	-	-	4,650	chief financial officer
Mar 07, 2024	fleming zachary b.	acquired	-	-	12,693	chief executive officer
Mar 01, 2024	mcneil michael d.	sold (taxes)	-50,102	38.96	-1,286	chief financial officer
Mar 01, 2024	fleming zachary b.	sold (taxes)	-66,855	38.96	-1,716	chief executive officer
Feb 01, 2024	mcneil michael d.	sold (taxes)	-13,184	33.72	-391	chief financial officer
Feb 01, 2024	fleming zachary b.	sold (taxes)	-14,398	33.72	-427	chief executive officer
Jan 01, 2024	fleming zachary b.	sold (taxes)	-51,580	41.1	-1,255	chief executive officer
Sep 21, 2023	fleming zachary b.	sold (taxes)	-25,438	37.19	-684	chief executive officer
Jun 01, 2023	ortwein sara n	acquired	-	-	2,802	-

Which funds bought or sold SMTI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	DEUTSCHE BANK AG\	reduced	-5.27	-17,563	101,750	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-24.26	-138,748	297,406	-%
May 15, 2024	Royal Bank of Canada	added	551	301,000	363,000	-%
May 15, 2024	Lee Financial Co	sold off	-100	-20,550	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-10.23	-2,081	8,769	-%
May 15, 2024	Diametric Capital, LP	reduced	-29.21	-202,826	356,421	0.20%
May 15, 2024	BARCLAYS PLC	reduced	-49.42	-120,000	100,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-45.27	-78,480	76,220	-%
May 15, 2024	STEPHENS INC /AR/	unchanged	-	-37,396	337,477	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	5.87	-11,000	215,000	-%

Are Funds Buying or Selling SMTI?

Are funds buying SMTI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SMTI

No. of Funds

Recent SEC filings of Sanara MedTech Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	DEFA14A	DEFA14A
May 15, 2024	DEFA14A	DEFA14A
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	3	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 15, 2024	DEFA14A	DEFA14A
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Sanara MedTech Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.9B	40.3B	-3.99%	-4.43%	32.33	4.51	-2.84%	-3.08%
BDX	68.5B	19.7B	1.04%	-5.28%	51.42	3.48	4.82%	-17.56%
ALGN	21.1B	3.9B	-8.05%	-4.13%	45.63	5.39	5.72%	46.72%
BAX	18.1B	14.9B	-11.51%	-17.62%	6.82	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.53%	24.43%	31.2	2.75	6.16%	35.06%
HSIC	9.6B	12.5B	5.70%	-3.02%	24.67	0.77	-0.61%	-18.83%
BIO	8.6B	2.6B	0.13%	-21.80%	-26.61	3.29	-6.25%	-68.62%
XRAY	5.9B	3.9B	-8.58%	-30.13%	-62.71	1.49	0.23%	91.03%
AXNX	3.5B	387.1M	0.52%	27.70%	-216.75	8.92	30.82%	65.57%
PDCO	2.3B	6.6B	1.85%	-3.48%	11.96	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-0.51%	-11.36%	-1.88	0.4	7.94%	-1661.78%
ANIK	386.7M	169.3M	3.28%	2.59%	-5.03	2.28	7.49%	-244.90%
ANGO	254.7M	324.0M	0.79%	-32.56%	-1.32	0.79	-3.19%	-337.41%
APYX	48.8M	50.5M	2.90%	-74.91%	-2.14	0.97	14.25%	-10.06%
AEMD	1.0M	3.7M	-72.41%	25.00%	-0.09	0.28	5.77%	8.23%

Sanara MedTech Inc. News

Latest updates

Sanara MedTech Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.8%	18,536,638	17,689,813	16,024,948	15,753,164	15,521,917	15,316,273	13,044,571	9,670,778	7,811,223	7,033,408	5,823,942	6,277,133	5,009,436	3,305,547	4,306,324	2,967,183	6,491,514	3,353,096	2,909,282	3,017,489	2,486,896
Cost Of Revenue	5.7%	1,890,046	1,788,162	1,751,349	2,187,516	2,125,659	2,369,123	2,228,561	958,086	805,081	782,772	517,611	536,405	474,433	489,827	447,935	348,675	330,188	299,967	285,164	334,829	289,340
Gross Profit	4.7%	16,646,592	15,901,651	14,273,599	13,565,648	13,396,258	12,947,150	10,816,010	8,712,692	7,006,142	6,250,636	5,306,331	5,740,728	4,535,003	4,299,311	3,858,389	2,618,508	3,194,143	3,053,129	2,624,118	2,682,660	2,197,556
Operating Expenses	12.7%	18,178,299	16,127,646	15,180,254	15,431,828	14,612,581	16,070,324	14,048,152	12,097,684	9,783,014	9,663,041	7,160,349	6,766,932	5,618,533	5,151,369	5,165,304	3,698,248	4,990,043	4,515,690	3,421,337	3,005,790	2,354,703
S&GA Expenses	-0.9%	16,192,259	16,336,329	13,877,879	13,811,476	12,969,069	14,110,370	12,062,195	10,428,133	9,375,630	9,161,197	6,920,105	6,562,144	5,409,730	5,063,389	5,072,402	3,582,511	4,932,151	4,418,383	3,315,575	2,983,248	2,350,363
R&D Expenses	45.2%	946,298	651,519	986,454	1,177,128	1,317,324	1,034,008	1,061,387	1,067,000	204,637	300,837	35,674	103,981	118,212	6,217	11,022	41,516	4,387	-	-	-	-
EBITDA Margin	22.0%	-0.04	-0.05	-0.11	-0.15	-0.21	-0.25	-0.27	-0.25	-0.21	-0.24	-0.11	-0.02	-0.03	-	-	-	-	-	-	-	-
Interest Expenses	-7.0%	267,336	287,483	188,294	-	6.00	111,630	109,689	63,427	-	-	-	-	711	615	1,458	1,101	8,354	24,994	46,014	29,486	5,425
Income Taxes	-	-	-	-	-	-	-	-1,702,890	-4,141,906	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-262,444	-1,094,949	-1,866,180	-	-4,163,485	-3,232,142	-3,384,992	-	-3,556,585	-2,047,861	-	-	-	-	-	-	-	-	-	-
EBT Margin	4.4%	-0.11	-0.11	-0.17	-0.21	-0.27	-0.31	-0.33	-0.29	-0.24	-0.26	-0.13	-0.04	-0.05	-	-	-	-	-	-	-	-
Net Income	-787.6%	-1,764,184	-198,756	-1,060,370	-1,866,180	-1,216,329	-4,107,139	-1,470,460	756,914	-3,156,505	-3,484,704	-2,047,861	-1,205,973	-1,183,376	-266,453	-1,208,123	-1,129,557	-1,841,012	1,550,965	-836,976	-352,471	-162,572
Net Income Margin	-7.6%	-0.07	-0.07	-0.13	-0.15	-0.11	-0.17	-0.26	-0.33	-0.37	-0.33	-0.23	-0.20	-0.24	-	-	-	-	-	-	-	-
Free Cashflow	-83.9%	-1,660,188	-902,808	893,818	-1,732,794	-1,769,018	-698,380	-1,655,818	-1,190,512	-2,157,175	-1,926,068	-1,438,984	-355,346	-1,265,995	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q2	2019Q1	2018Q4
Assets	-4.0%	70,912	73,871	75,474	58,279	59,967	61,035	61,477	46,478	33,934	36,396	37,928	38,785	39,018	9,826	9,652	10,090	9,525	11,117	3,480	3,257	1,709
Current Assets	-9.6%	17,187	19,006	19,375	18,178	19,008	20,617	20,573	19,827	22,494	24,608	27,230	28,919	31,540	4,482	5,283	6,109	6,790	8,856	3,194	2,938	1,691
Cash Equivalents	-45.1%	2,828	5,147	6,236	6,060	7,286	8,959	10,285	12,679	16,143	18,653	22,371	24,389	27,329	455	2,120	3,305	4,022	6,612	419	742	176
Inventory	-10.4%	4,229	4,718	5,021	4,421	3,432	3,549	3,734	2,312	2,171	2,048	1,552	1,538	1,179	1,148	788	863	1,009	747	395	346	465
Net PPE	-5.3%	1,191	1,258	1,327	1,240	1,336	1,416	1,471	1,514	1,579	1,630	1,581	1,669	1,665	679	209	227	245	205	72.00	66.00	19.00
Goodwill	0%	3,602	3,602	3,602	3,602	3,602	3,602	3,278	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-4.7%	27,900	29,283	31,376	17,314	18,489	19,315	16,829	11,027	5,418	6,244	4,505	4,127	3,546	3,986	4,088	4,477	2,968	4,725	4,567	3,990	1,123
Current Liabilities	-7.4%	12,746	13,768	13,227	9,881	10,602	12,806	9,206	6,930	5,231	6,022	4,158	3,746	3,133	3,540	3,093	3,588	2,517	2,640	2,896	2,313	1,123
Long Term Debt	-3.8%	8,768	9,113	9,458	-	-	-	-	-	-	-	-	-	-	-	468	393	-	-	-	-	-
LT Debt, Current	60.0%	929	580	232	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	9,113	9,458	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-4.1%	43,012	44,832	44,317	40,964	41,479	41,828	44,648	39,465	28,516	30,152	33,423	34,657	35,472	5,840	5,563	5,614	6,557	6,392	-	2.00	587
Retained Earnings	-6.6%	-29,898	-28,036	-27,799	-26,740	-24,913	-23,394	-19,116	-21,660	-18,415	-15,235	-11,405	-9,385	-8,213	-7,032	-6,785	-5,638	-4,512	-2,675	-375	-24.29	138
Additional Paid-In Capital	0.4%	73,180	72,861	72,108	67,881	66,529	65,214	64,566	57,851	47,438	45,868	45,301	44,488	44,190	13,177	12,633	11,476	11,289	-2,081	-12,080	-12,079	-10,919
Accumulated Depreciation	11.1%	1,329	1,196	-	-	-	740	-	-	-	343	252	160	142	125	107	91.00	76.00	61.00	74.00	76.00	511*
Shares Outstanding	1.0%	8,623	8,535	8,540	8,440	8,385	8,300	8,107	7,699	7,606	7,677	7,280	7,159	6,817	6,297	-	-	-	-	-	-	-
Minority Interest	-14.3%	-279	-244	-219	-184	-145	-107	-809	-748	-515	-488	-480	-452	-512	-310	-290	-229	-225	-221	-1.05	-	-
Float	-	-	-	-	151,157	-	-	-	69,503	-	-	-	113,199	-	-	-	22,923	-	-	6,526	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-87.9%	-1,594	-848	1,064	-1,719	-1,741	-645	-1,643	-1,154	-2,112	-1,784	-1,434	-334	-1,261	-591	-711	-700	-2,032	-833	-94.31	-803	-436
Share Based Compensation	-6.6%	803	861	858	1,127	597	731	683	703	585	1,817	229	298	326	530	382	97.00	394	-	-	-	-
Cashflow From Investing	-21.3%	-65.82	-54.28	-10,113	-12.94	-27.05	-376	-750	-2,089	-294	-1,491	-583	-2,605	-604	-1,086	-500	-600	-557	-515	-1,164	-19.87	502
Cashflow From Financing	-254.4%	-658	-185	9,225	507	96.00	-304	-	-220	-102	-442	-	-	28,739	13.00	26.00	583	-	7,800	1,000	500	500
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.06	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SMTI Income Statement

2024-03-31

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net Revenue	$ 18,536,638	$ 15,521,917
Cost of goods sold	1,890,046	2,125,659
Gross profit	16,646,592	13,396,258
Operating expenses
Selling, general and administrative expenses	16,192,259	12,969,069
Research and development	946,298	1,317,324
Depreciation and amortization	1,105,420	778,875
Change in fair value of earnout liabilities	(65,678)	(452,687)
Total operating expenses	18,178,299	14,612,581
Operating loss	(1,531,707)	(1,216,323)
Other expense
Interest expense and other	(267,336)	(6)
Total other expense	(267,336)	(6)
Net loss	(1,799,043)	(1,216,329)
Less: Net loss attributable to noncontrolling interest	(34,859)	(38,429)
Net loss attributable to Sanara MedTech shareholders	$ (1,764,184)	$ (1,177,900)
Net loss per share of common stock, basic	$ (0.21)	$ (0.14)
Net loss per share of common stock, diluted	$ (0.21)	$ (0.14)
Weighted average number of common shares outstanding, basic	8,419,528	8,173,784
Weighted average number of common shares outstanding, diluted	8,419,528	8,173,784

SMTI Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash	$ 2,828,234	$ 5,147,216
Royalty receivable		49,344
Inventory, net	4,229,150	4,717,533
Prepaid and other assets	911,594	608,411
Total current assets	17,186,779	19,005,869
Long-term assets
Intangible assets, net	43,953,610	44,926,061
Goodwill	3,601,781	3,601,781
Investment in equity securities	3,084,278	3,084,278
Right of use assets – operating leases	1,894,687	1,995,204
Property and equipment, net	1,190,805	1,257,956
Total long-term assets	53,725,161	54,865,280
Total assets	70,911,940	73,871,149
Current liabilities
Accrued bonuses and commissions	6,893,381	7,676,770
Accrued royalties and expenses	2,288,428	2,047,678
Earnout liabilities – current	979,488	1,100,000
Current portion of debt	928,571	580,357
Operating lease liabilities – current	377,273	361,185
Total current liabilities	12,746,073	13,767,877
Long-term liabilities
Long-term debt, net of current portion	8,767,991	9,113,123
Earnout liabilities – long-term	2,777,835	2,723,001
Operating lease liabilities – long-term	1,626,130	1,737,445
Other long-term liabilities	1,982,345	1,941,686
Total long-term liabilities	15,154,301	15,515,255
Total liabilities	27,900,374	29,283,132
Commitments and contingencies (Note 8)
Shareholders’ equity
Common Stock: $0.001 par value, 20,000,000 shares authorized; 8,622,739 issued and outstanding as of March 31, 2024 and 8,535,239 issued and outstanding as of December 31, 2023	8,623	8,535
Additional paid-in capital	73,180,208	72,860,556
Accumulated deficit	(29,898,146)	(28,036,814)
Total Sanara MedTech shareholders’ equity	43,290,685	44,832,277
Equity attributable to noncontrolling interest	(279,119)	(244,260)
Total shareholders’ equity	43,011,566	44,588,017
Total liabilities and shareholders’ equity	70,911,940	73,871,149
Nonrelated Party [Member]
Current assets
Accounts receivable	9,194,799	8,474,965
Current liabilities
Accounts payable	1,191,816	1,924,082
Related Party [Member]
Current assets
Accounts receivable	23,002	8,400
Current liabilities
Accounts payable	$ 87,116	$ 77,805

About Sanara MedTech Inc.

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; BiakoÃ‚Â¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; BiakoÃ‚Â¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and BiakoÃ‚Â¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

WEBSITE	https://sanaramedtech.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	101

Sanara MedTech Inc. Frequently Asked Questions

What is the ticker symbol for Sanara MedTech Inc.? What does SMTI stand for in stocks?

SMTI is the stock ticker symbol of Sanara MedTech Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sanara MedTech Inc. (SMTI)?

As of Wed May 15 2024, market cap of Sanara MedTech Inc. is 293.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SMTI stock?

You can check SMTI's fair value in chart for subscribers.

What is the fair value of SMTI stock?

You can check SMTI's fair value in chart for subscribers. The fair value of Sanara MedTech Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sanara MedTech Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SMTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sanara MedTech Inc. a good stock to buy?

The fair value guage provides a quick view whether SMTI is over valued or under valued. Whether Sanara MedTech Inc. is cheap or expensive depends on the assumptions which impact Sanara MedTech Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SMTI.

What is Sanara MedTech Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, SMTI's PE ratio (Price to Earnings) is -60.08 and Price to Sales (PS) ratio is 4.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SMTI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sanara MedTech Inc.'s stock?

In the past 10 years, Sanara MedTech Inc. has provided 0.781 (multiply by 100 for percentage) rate of return.